Physician profile
James Wehmeier
NPI 1992417059
$1,812.68
in general payments reported to CMS, 2019-2025
21 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $649 · 2024: $895 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $251.80 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $233.18 | 2023-2024 | Farxiga, Breztri |
| Amgen INC. | $216.15 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $174.01 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $163.16 | 2023-2024 | |
| Abbvie INC. | $138.38 | 2023-2025 | |
| Scpharmaceuticals INC. | $93.42 | 2024 | |
| Axsome Therapeutics, INC. | $77.55 | 2025 | Symbravo |
| Tris Pharma INC | $75.93 | 2023-2024 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.63 | 2023-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $71.72 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $54.07 | 2023-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $37.76 | 2023 | |
| Livanova USA, INC. | $27.57 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mannkind Corporation | $21.44 | 2023 | Afrezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.83 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $18.49 | 2024 | Eliquis |
| Merz Pharmaceuticals, LLC | $18.21 | 2025 | Xeomin |
| Nevro Corp. | $16.61 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $15.48 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.29 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wehmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.